Compare CASI & NAII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CASI | NAII |
|---|---|---|
| Founded | 1991 | 1980 |
| Country | China | United States |
| Employees | N/A | 234 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7M | 21.6M |
| IPO Year | 1996 | 1987 |
| Metric | CASI | NAII |
|---|---|---|
| Price | $0.82 | $2.56 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 26.1K | 15.7K |
| Earning Date | 03-30-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $26,846,000.00 | ★ $135,157,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.72 | 10.92 |
| 52 Week Low | $0.74 | $2.57 |
| 52 Week High | $3.09 | $4.96 |
| Indicator | CASI | NAII |
|---|---|---|
| Relative Strength Index (RSI) | 38.96 | 26.77 |
| Support Level | $0.74 | $3.32 |
| Resistance Level | $0.97 | $3.50 |
| Average True Range (ATR) | 0.09 | 0.33 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 19.74 | 12.70 |
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products, to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segments. The company derives the majority of revenue from Private-Label Contract Manufacturing, which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.